Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
11 evidence topics · 15 sources
Summary: histologic diagnosis, grading, and molecular testing
ACC is diagnosed by biopsy with histology and immunohistochemistry, after CT or MRI to define local extent and stage. Grading is based on the solid component: the Perzin/Szanto system uses a >30% solid cutoff, the Spiro system >50%, the van Weert system the presence of any solid component, and the WHO notes a worse course when the solid component exceeds one third of the tumor. Interobserver agreement was moderate for the Perzin/Szanto (kappa 0.393) and Spiro (kappa 0.433) systems and 0.990 for the van Weert system. High-grade transformation is distinguished from solid ACC by nuclear enlargement and irregularity, higher mitotic counts, and loss of biphasic differentiation.
Molecular testing supports diagnosis and subtyping. MYB::NFIB FISH had 42.9% sensitivity and 100% specificity, and a MYB RNA in situ hybridization model had 93.2% sensitivity and 97.1% specificity in 79 cases. ACC-I and ACC-II can be assigned with MYC and p63 immunohistochemistry (AUROC 0.99). NOTCH pathway activation can be identified by genomic sequencing or NICD1 immunohistochemistry.